Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $2.98B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.37M
Average 2.42M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +106.4% | +17.9% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +106.4% over three years. Forward estimates point to Revenue at +17.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -21.14% |
Autolus Therapeutics plc NASDAQ:AUTL | $311.41M | $1.17 | Not rated | -1.4 | -22.87% |
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +155.37% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -47.07% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | $7.57 | Not rated | -1.9 | +43.36% |
Cartesian Therapeutics, Inc. NASDAQ:RNAC | $193.69M | $6.35 | Not rated | -1.7 | -17.62% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | -3.81% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | $1.18 | Not rated | -4.6 | -77.64% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | $7.70 | Not rated | -14.7 | -53.86% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -73.11% |
Continue the stock analysis
Jump to another research area for this company.